证券代码：300007 证券简称：汉威科技 公告编号：2026-007 汉威科技集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2026 年 02 月 02 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 02 月 02 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2026 年 02 月 02 日 9:15 至 15:00 的 任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 01 月 27 日 7、出席对象： （1）截至股权登记日下午收市时，在中国证券登记结算有限责任公司深 圳分公司登记在册的公司全体股东均有权出席股东会，并可以以书面形式（附 件二：授权委托书）委托代理人出席会议和参加表决，该股东代理人可不必是 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董 ...

证券代码：300007 证券简称：汉威科技 公告编号：2026-003 汉威科技集团股份有限公司 第六届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次会议通知于 2026 年 1 月 12 日以邮件或通讯方式送达。 2、本次会议于 2026 年 1 月 16 日在公司会议室以现场结合通讯的方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、本次会议由董事长任红军先生主持，公司副总经理、董事会秘书肖锋先 生列席了会议。 5、本次董事会的召集、召开和表决程序符合《中华人民共和国公司法》及 《公司章程》的有关规定，表决所形成的决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司董事会换届选举暨提名第七届董事会非独立董事候 选人的议案》 鉴于公司第六届董事会任期即将届满，公司根据《公司法》及《公司章程》 等有关规定进行董事会换届选举。经公司董事会提名委员会资格审核，公司董事 会同意提名任红军先生、李志刚先生、尚中锋先生、杨昌再先生、肖锋先生为第 七届董事会非独立董事 ...

Core Insights - Qingdao Zhenghe Industrial Co., Ltd. hosted the "Embodied Intelligent Dexterous Hand Development Forum and Global Launch of the Chain Dexterous Hand" in Shanghai, introducing the world's first chain dexterous hand, CHOHOHand [1][5] Group 1: Product Features - The CHOHOHand features eight core advantages: high load capacity, high resistance, high reliability, high durability, high precision, high energy efficiency, low weight, and low cost, making it an all-around "octagonal warrior" in the dexterous hand industry [5][6] - The product boasts 17 degrees of freedom (7 active + 10 passive), with a fingertip repeat positioning accuracy of ±0.1mm, a single-hand load capacity exceeding 40kg, and a cycle life of over 1 million actions [6][8] - The chain transmission efficiency reaches 95%-98%, allowing for a balance between high precision and high load requirements, with a maintenance cost of only 730 yuan over a 5-year lifecycle [6][8] Group 2: Market and Industry Context - The global dexterous hand market is experiencing rapid growth, with a compound annual growth rate of 110% over the past five years [8] - The launch of CHOHOHand fills a gap in the chain-driven dexterous hand sector and supports the industrial application of embodied intelligence technology [8] - The product is expected to shift China's robotics core components from a "follower" to a "leader" position in the global manufacturing upgrade [8] Group 3: Strategic Partnerships and Development - Zhenghe Industrial has signed strategic cooperation agreements with multiple companies and research institutions to accelerate technology transfer and industrial upgrades [7] - The company aims to leverage the complete industrial ecosystem in Zhangjiang to enhance core technology transformation and release stronger innovative vitality [7] - Collaborative efforts will focus on the technical iteration, market expansion, and scene implementation of the chain dexterous hand, promoting high-quality development in the embodied intelligence industry [7]

Core Viewpoint - Hanwei Technology's stock price has shown fluctuations, with a recent decline of 2.00% and a year-to-date increase of 8.62%, indicating mixed market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Hanwei Technology achieved a revenue of 1.702 billion yuan, representing a year-on-year growth of 8.44%. The net profit attributable to shareholders was 84.843 million yuan, reflecting a growth of 6.33% compared to the previous year [2]. - Cumulatively, since its A-share listing, Hanwei Technology has distributed a total of 239 million yuan in dividends, with 9.481 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 79,400, up by 6.87%. The average number of circulating shares per person decreased by 6.43% to 3,566 shares [2]. - The stock's trading activity showed a net outflow of 96.6541 million yuan from major funds, with significant buying and selling activity from large orders [1]. Institutional Holdings - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Penghua Carbon Neutral Theme Mixed A and an increase by Hong Kong Central Clearing Limited. New entrants include several funds such as E Fund National Robot Industry ETF and Huashang Runfeng Mixed A [4].

Group 1 - The core viewpoint of the article highlights the performance of the Zhongzheng 2000 ETF (159531), which rose by 1.99% to 1.534 yuan with a trading volume of 125 million yuan as of the midday close [1] - The top-performing stocks within the Zhongzheng 2000 ETF include Shijia Photon, which increased by 1.99%, Huasheng Tiancai by 4.81%, Meiri Interactive by 13.16%, and others showing significant gains [1] - The Zhongzheng 2000 ETF has a performance benchmark of the Zhongzheng 2000 Index return, managed by Southern Fund Management Co., Ltd., with a return of 49.77% since its establishment on September 7, 2023, and an 11.24% return over the past month [1]

Core Viewpoint - Zhengzhou High-tech Zone is establishing itself as a new benchmark for high-quality development through a five-dimensional highland approach, focusing on innovation and technology-driven industries. Economic Performance - In the first three quarters of 2025, Zhengzhou High-tech Zone achieved a GDP of 48.27 billion yuan, representing a year-on-year growth of 5.2%, an increase of 1.3 percentage points compared to the same period in 2024 [1]. Innovation Ecosystem - The zone has attracted over 110,000 business entities, 80,000 enterprises, and 120,000 technology talents, forming a modern industrial system characterized by "2+4+3" [2]. - Zhengzhou High-tech Zone is home to 654 provincial-level and above research platforms, including 33 national-level ones, showcasing its strong innovation capabilities [5]. Industry Development - The zone has been recognized as a key cultivation area for "advanced computing internet" and "new hydrogen fuel cells," being the only high-tech zone in the province to receive such recognition [5]. - The sensor industry has seen rapid growth, with over 2,900 related enterprises established, covering various applications from gas to agriculture [10]. Policy Environment - Zhengzhou High-tech Zone has implemented various policies to optimize the business environment, including measures to support enterprises in reducing costs and enhancing efficiency [13][15]. - The government has established a comprehensive financial service system, with a fund scale of 17 billion yuan and a venture capital management scale exceeding 195 billion yuan [18]. Talent Development - The zone has attracted a significant number of high-level talents, including 24 academicians and 12 national-level candidates, contributing to its innovation-driven development [19]. - A new talent policy has been introduced, offering up to 20 million yuan in support to attract young talents and stimulate enterprise recruitment [20]. Cultural Integration - Zhengzhou High-tech Zone is integrating cultural heritage with modern innovation, promoting industries like micro-short films and animation, which have become significant cultural assets [22][25].

Core Insights - Elon Musk's technological ecosystem is rapidly evolving, integrating six key industries: commercial space (SpaceX), brain-machine interfaces (Neuralink), humanoid robots (Optimus), autonomous driving (FSD), artificial intelligence (X AI), and hyperloop (The Boring Company) [1][19] - The technological advancements and mass production efforts are reshaping the global tech industry landscape and presenting certain investment opportunities for domestic companies in related sectors [1][19] Group 1: Deep Binding from Components to System Integration - The production of Tesla's Optimus robot is set to begin, with a target of 100,000 units by 2026, but the localization rate of core components is still below 30%, leaving significant market penetration opportunities for domestic high-barrier companies [21] - Top Group is a core supplier for Tesla's vehicle chassis and has entered the testing phase for Optimus's rotating joints, showcasing strong system integration capabilities [21] - Greentech Harmonic is a leading global harmonic reducer supplier, with its Y series products passing Tesla's extreme conditions test and set to deliver 10,000 units by 2025 [21] - Sanhua Intelligent Control is leveraging its experience in automotive thermal management to quickly enter the robot electromechanical actuator and thermal management systems market [21] - Mingzhi Electric is one of the few companies capable of mass-producing hollow cup motors, which are critical for achieving human-like dexterity in robotic hands [21] Group 2: L5 Autonomous Driving - Hardware and Software Integration - Tesla's Full Self-Driving (FSD) is accelerating its rollout, with deep participation from the Chinese supply chain in hardware iteration and software adaptation [22] - Desay SV is supplying the autonomous driving domain controller to Tesla's North American supply chain, with FSD-related orders expected to reach 1.2 billion yuan by 2025 [22] - Lianchuang Electronics is the main supplier of vehicle-mounted lenses for Tesla's HW4.0, holding approximately 60% market share [22] - Zhongke Chuangda, as a leading vehicle operating system provider, is continuously optimizing AI model efficiency on Tesla's platform to support smooth FSD software deployment [22] Group 3: Technical Collaboration - Patent Sharing and Capability Building - Some companies, while not supplying on a large scale, are building long-term barriers through technical cooperation [23] - Changying Precision has reached a cross-licensing agreement with Tesla regarding flexible sensors, enhancing its technological moat in robot perception [23] - Sanhua Intelligent Control is jointly developing actuator efficiency optimization solutions to enhance Optimus's operational endurance [24] - Yanshan Technology's pure vision autonomous driving solution aligns closely with FSD technology, currently supporting Tesla indirectly through international Tier 1 suppliers [24] Group 4: Potential Tracks - From Benchmarking to Entry - In commercial space, Chinese companies are gaining certification in key areas as SpaceX's Starlink accelerates deployment [25] - Tongyu Communication has developed a microwifi antenna module that has passed SpaceX interface certification, expected to supply 60% of Starlink's dedicated modules starting Q3 2025 [25] - Xinyi Communication's subsidiary is the exclusive supplier of high-frequency connectors for Starlink ground terminals, with annual revenue projected to exceed 1.5 billion yuan [25] - Blue Arrow Aerospace is the only domestic company mastering reusable liquid oxygen-methane rocket technology, establishing a significant barrier in low-cost, high-frequency launches [25] Group 5: Brain-Machine Interfaces - Complementary Paths for Cooperation - Neuralink focuses on invasive methods, while Chinese companies are exploring non-invasive and clinical translation paths [30] - Yanshan Technology's non-invasive BCI technology complements Neuralink's approach, indicating clear cooperation potential if Neuralink expands into consumer products [30] - Hanwei Technology's subsidiary has developed ultra-flexible sensors that are cost-competitive and have entered the international supply chain [30] - Sanbo Brain Science is the only private hospital in China with clinical implantation qualifications for brain-machine interfaces, performing over 30,000 surgeries annually [30] Group 6: Indirect Competition and Strategic Value - Some companies, while not directly collaborating with Musk's ecosystem, play a crucial role in national projects, fulfilling "domestic substitution" responsibilities [31] - China Satellite and China Satcom are leading the "Star Network Project," competing with Starlink in satellite manufacturing and operations [31] - Cambrian is developing AI chips that meet xAI's computational needs, presenting potential entry points if Tesla or xAI expands their supply chains [32] - Four-dimensional Map has over 60% market share in high-precision mapping, providing core positioning services for Tesla in China [33] Group 7: Selection Logic for "Invisible Champions" - Companies that meet the criteria of "technological leadership, low public recognition, high industry relevance, and sustained innovation barriers" have emerged as key players [34] - Mingzhi Electric is a global leader in hollow cup motors, essential for dexterous robotic hands [34] - Sanhua Intelligent Control is a dual leader in thermal management and actuators, validated by Tesla [34] - Top Group excels in system integration from chassis to joint assembly, showcasing deep binding [34] - Industrial Fulian is the largest server manufacturer globally, benefiting directly from xAI's computational expansion [34] - Blue Arrow Aerospace is the only player in liquid oxygen-methane reusable rockets, shaping the future of China's commercial space industry [34]

证券代码：300007 证券简称：汉威科技 公告编号：2026-002 汉威科技集团股份有限公司 关于完成经营范围工商变更登记、《公司章程》备案并换发营业 执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 汉威科技集团股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召 开第六届董事会第二十五次会议、于 2025 年 11 月 18 日召开 2025 年第二次临时 股东大会，审议通过了《关于变更经营范围及修订<公司章程>的议案》。具体内 容详见公司于 2025 年 10 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于变更经营范围及修订<公司章程>的公告》（公告编号：2025-054）。 二、进展情况 近日，公司已完成经营范围工商变更登记、《公司章程》备案手续，并取得 了河南省市场监督管理局换发的《营业执照》，具体信息如下： 名称：汉威科技集团股份有限公司 经营范围：许可项目：建设工程施工（除核电站建设经营、民用机场建设）； 建筑智能化系统设计；建设工程设计；特种设备检验检测；测绘服务（依法 ...

Core Insights - The article discusses the rapid advancement and commercialization of brain-computer interface (BCI) technology in China, driven by policy support and significant capital investment [1][5][9]. Technological Breakthroughs - Recent breakthroughs in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegic patients to control devices like smart wheelchairs and robotic dogs [5][6]. - Companies like JieTi Medical and ChipSmart have made significant progress, with JieTi completing three invasive clinical trials and ChipSmart's semi-invasive product achieving successful human implants [5][6]. - The BCI technology is categorized into non-invasive, semi-invasive, and invasive types, each with its advantages and disadvantages [5]. Policy and Capital Support - The Chinese government has identified BCI as one of the six future industries in the 14th Five-Year Plan, providing a strategic framework for its development [8][9]. - Recent policy initiatives include the establishment of independent billing for BCI services by the National Medical Insurance Administration, with several provinces setting clear pricing for BCI medical services [8][9]. - The National Medical Products Administration has also initiated standards for BCI technology, which will help reduce costs and risks associated with clinical applications [8][9]. Market Opportunities - The BCI market is expected to grow significantly, with a focus on medical applications for conditions like stroke, epilepsy, and paralysis, where patients show a strong willingness to adopt early products [6][7]. - The integration of BCI technology with artificial intelligence and robotics could open up a trillion-dollar market space in the long term [11]. Industry Standardization - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [10]. - The domestic BCI industry benefits from strong policy support, a vast clinical resource base, and a complete supply chain, which are crucial for its growth [10]. Investment Landscape - Investment firms highlight the dual nature of BCI as both a medical and technology investment, emphasizing the importance of identifying policy-supported "true BCI" targets [11]. - The potential for leading Chinese BCI companies to emerge on the global stage is significant, given the country's advancements in technology and supportive investment environment [11].

Core Insights - The brain-computer interface (BCI) industry in China is experiencing significant advancements, with clinical results emerging for high-level paraplegics and substantial funding rounds, including a recent 2 billion yuan investment in a non-invasive unicorn company, Strong Brain Technology, marking the second-largest funding record globally in this field [1][2] - The industry is poised for rapid commercialization, driven by technological breakthroughs, capital influx, and supportive policies, as it transitions from cutting-edge technology to practical applications in daily life [1][5] Technological Breakthroughs - Recent advancements in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegics to control smart wheelchairs and robotic dogs [2][3] - Companies like JieTi Medical and Chip Intelligence have made significant progress, with JieTi completing trials for its invasive BCI system and Chip Intelligence's semi-invasive product achieving human implantation [2][3] - The first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology has shown promising results, allowing an 8-year paraplegic patient to achieve thought control just five days post-surgery [2][3] Policy and Capital Support - The BCI sector benefits from comprehensive policy support, including its designation as one of the six future industries in the 14th Five-Year Plan, which elevates it to a national strategic priority [5][6] - Recent initiatives by the Sichuan provincial medical insurance bureau have established pricing for 82 neuro-related medical services, including BCI applications, facilitating clinical adoption [5][6] - The establishment of industry standards by the National Medical Products Administration is expected to lower costs and risks associated with technology development and clinical application [6] Industry Collaboration and Investment - Companies like Baiyang Pharmaceutical are actively collaborating with academic institutions to explore the integration of BCI with artificial intelligence, aiming for innovative clinical solutions [7] - Other listed companies are also engaging in the BCI space through material supply and equipment development, indicating a strong interest from institutional investors [7] Future Development and Challenges - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [8] - Potential constraints include the pace of chip design and production, as well as the need for ethical regulations regarding personal brain data [8] - Despite these challenges, the domestic BCI industry holds significant advantages, including strong policy support, a vast clinical resource base, and a comprehensive supply chain [8] Investment Opportunities - The BCI sector presents a dual investment opportunity in both medical and technological domains, with short-term focus on disease treatment and long-term potential for enhancing human capabilities through integration with AI and robotics [9] - The industry is positioned to cultivate leading global BCI companies, fostering a capital-innovation synergy between primary and secondary markets [9]